Cited 0 times in 
Cited 0 times in 
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy
https://orcid.org/0000-0001-7948-1350Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.